Activity of low dose nivolumab in patients with advanced squamous cell carcinomas and other cancers
A retrospective study of 53 patients with advanced cancers, primarily squamous cell carcinomas, found that low-dose nivolumab (20 mg every three weeks) demonstrated encouraging efficacy and manageable toxicity comparable to standard doses, particularly in a frail, elderly population.